We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
Raccoonpox virus is an orthopoxvirus. As with the two known North American orthopoxviruses, skunkpox and volepox viruses, which collectively comprise a separate group, remarkably little is known about its epidemiology. Although the raccoonpox virus was identified from a cat in Canada that had a condition that resembled cowpox, it seems to be highly host-specific. In the northeastern United States, the raccoonpox virus was first discovered in the lungs of healthy-looking raccoons, and serological investigations in the same region revealed that more than 20% of wild raccoons had antibodies to the virus. Additionally, experimental raccoon infection did not result in any overt illness. As a result of the raccoonpox virus's limited host range, low zoonotic and harmful potential, and endemic nature in North America, recombinant vaccines for use in American wildlife species.
Background of Raccoonpox Virus
Raccoonpox virus (RCN) is an orthopoxvirus belonging to the Poxviridae family and subfamily Chordopoxvirinae. It has double-stranded DNA. More specifically, RCN's natural hosts are raccoons. It has brick-shaped virion geometries and is an enveloped virus. It features monopartite genomic segmentation and a linear genomic layout. It is a big virus particle with a 150–300 kbp dsDNA genome (Ropp). The genome has a hairpin loop at each end. The genome has a 35 percent Guanine/Cytosine (G-C) composition. The genome of the RCN virus has sizable areas where hybridization between species of the same genus occurs.
Epidemiology of Raccoonpox
In a Maryland screening of raccoons that appeared to be in good condition, the RCNV was first identified in 1961. Many people think that because it has no recognized disease in any species (including raccoons), its "natural" host may yet be unidentified. Several animals, including mice, prairie dogs, cats, and raccoons, have been successfully immunized with this virus as a wild mammal vaccine without developing any concomitant disease. RCNV, like vaccinia, has a sizable genome and the ability to carry and express a number of transgenes.
Application of Raccoonpox
For the delivery of vaccines against the plague, feline panleukopenia virus, rabies virus, and other infections in wild and domestic animals, RCN has been produced as a recombinant. To stop diseases like the plague from spreading to people, it's crucial to control their occurrence in wild and domestic animals. RCN is preferred over other potential poxvirus vectors for wildlife and veterinary management because it causes an immune response when ingested through mucosal pathways, which is crucial for the extensive immunization of wildlife. Recombinant RCN (rRCN) vaccinations have been administered safely to a variety of mammalian species, including mice, raccoons, cats, and sheep.